Related Experiment Videos
Microbiology and management of otitis media
1Department of Pediatrics, Georgetown University, School of Medicine, Washington, DC.
Abstract:
Otitis media is a complex and multifactorial condition with four defined stages: myringitis, acute otitis media, secretory (serous) otitis media and chronic otitis media. Drugs utilized in its treatment are antihistamines, decongestants, mucolytic agents, non-steroidal anti-inflammatory agents, corticosteroids, vaccine therapy and antibiotics. The rationale for using antibiotics is that inflammation has been associated with the presence of virulent bacteria in all types of otitis media. In acute otitis media the major organisms, present are Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. In chronic otitis media these organisms, plus Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and anaerobic bacteria are all prevalent. The microbiological flora of the middle ear in secretory otitis media is almost identical with that in acute otitis media. Empirical therapy can be given in most instances of acute and serous otitis media. However, in cases of failure, in the immunocompromised and in instances of chronic otitis media, establishing the individual microbiology of the inflamed middle ear is very helpful. The growing resistance of H. influenzae and M. catarrhalis to amoxycillin, due to beta-lactamase production, increases the risk of treatment failure of acute and serous otitis media. By adding a beta-lactamase inhibitor (clavulanic acid) to amoxycillin, or using second-generation cephalosporins, clearance can be achieved. Management of chronic otitis media requires surgical correction, drainage and coverage of anaerobic bacteria with agents such as amoxycillin plus clavulanic acid, or clindamycin plus antimicrobials against other pathogens such as Pseudomonas spp. where present.
Insights
Otitis media treatment involves various drugs, with antibiotics crucial for bacterial infections. Understanding specific bacterial causes and resistance patterns, like amoxycillin resistance in Haemophilus influenzae and Moraxella catarrhalis, guides effective therapy.
Area of Science:
- Otolaryngology
- Infectious Diseases
- Pharmacology
Background:
- Otitis media is a common condition with four stages: myringitis, acute otitis media, secretory otitis media, and chronic otitis media.
- Treatment involves antihistamines, decongestants, anti-inflammatories, corticosteroids, vaccines, and antibiotics.
- Antibiotics are used due to the association of inflammation with virulent bacteria in all otitis media types.
Purpose of the Study:
- To review the microbiological causes and treatment strategies for different stages of otitis media.
- To highlight the challenges posed by antibiotic resistance in common otitis media pathogens.
- To discuss appropriate antimicrobial selection based on bacterial profiles and resistance.
Main Methods:
- Review of literature on otitis media stages, causative organisms, and therapeutic agents.
- Analysis of bacterial prevalence in acute, secretory, and chronic otitis media.
- Evaluation of antibiotic efficacy and resistance patterns, including beta-lactamase production.
Main Results:
- Key pathogens include Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis in acute and secretory otitis media.
- Chronic otitis media involves these plus Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and anaerobes.
- Increasing amoxycillin resistance in H. influenzae and M. catarrhalis necessitates alternative treatments like amoxycillin with clavulanic acid or cephalosporins.
Conclusions:
- Effective otitis media management requires understanding the specific microbial etiology and antibiotic resistance profiles.
- Treatment for acute and secretory otitis media may involve empirical therapy, but resistance warrants consideration of beta-lactamase inhibitors or alternative antibiotics.
- Chronic otitis media often requires surgical intervention alongside targeted antimicrobial therapy, including coverage for anaerobes and Pseudomonas species.